Učitavanje...
A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL): A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
To address therapeutic challenges in childhood relapsed ALL, a phase 1 study combining a survivin mRNA antagonist, EZN-3042, with re-induction chemotherapy was developed for pediatric patients with second or greater bone marrow relapses of B lymphoblastic leukemia. EZN-3042 was administered as a sin...
Spremljeno u:
| Izdano u: | J Pediatr Hematol Oncol |
|---|---|
| Glavni autori: | , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4238428/ https://ncbi.nlm.nih.gov/pubmed/24276047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MPH.0b013e3182a8f58f |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|